Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 crossover pharmacokinetic interaction study of JNJ-64417184 and JNJ-53718678 in healthy adults
NL-OMON48293Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of JNJ-64417184 and rilematovir in respiratory syncytial virus disease (RSV) (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Effect of JNJ-64417184 on the pharmacokinetics of JNJ-53718678 and Effect of JNJ-53718678 on the pharmacokinetics of JNJ-64417184. Started Sep 2019; status: active, not recruiting.
02
Drugs
JNJ-64417184rilematovir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on NL-OMON48293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48293.